Literature DB >> 11786573

Paratesticular rhabdomyosarcoma: report from the Italian and German Cooperative Group.

A Ferrari1, G Bisogno, M Casanova, C Meazza, L Piva, G Cecchetto, I Zanetti, T Pilz, A Mattke, J Treuner, M Carli.   

Abstract

PURPOSE: We report the experience of the German-Italian Cooperative Group with 216 pediatric patients with paratesticular rhabdomyosarcoma treated over 20 years. PATIENTS AND METHODS: At diagnosis, 198 patients had localized disease and 18 had distant metastases. Among the nonmetastatic patients, complete tumor resection was performed in 83% of cases. Evaluation of the retroperitoneal lymph nodes changed over the years from routine surgical staging to radiologic assessment. All patients received chemotherapy, which was reduced in intensity and duration for patients with low-risk features in subsequent protocols. Radiotherapy was administered to 10% of patients.
RESULTS: Among 72 patients with a negative retroperitoneal computed tomography (CT) scan, surgical assessment detected nodal involvement in only one case. Among 23 patients with enlarged nodes on CT scans, surgery confirmed nodal spread in 65% of patients. No differences in the rate of nodal involvement were observed over the years. With a median follow-up of 110 months, 5-year survival was 85.5% for the series as a whole, 94.6% for patients with localized disease, and 22.2% for metastatic cases. Retroperitoneal nodal recurrence was the major cause of treatment failure. Univariate analysis revealed the prognostic value of tumor invasiveness, size, and resectability, as well as of nodal involvement and age, in patients with localized tumor.
CONCLUSION: The outcome for patients with localized paratesticular rhabdomyosarcoma is excellent, despite the reduction in chemotherapy over the years: an alkylating agent-free and anthracycline-free regimen is adequate treatment for low-risk patients. Surgical assessment of the retroperitoneum must be reserved for patients with enlarged nodes on CT scans. Children over 10 years old carry a higher risk of nodal involvement and relapse.

Entities:  

Mesh:

Year:  2002        PMID: 11786573     DOI: 10.1200/JCO.2002.20.2.449

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  25 in total

1.  Embryonal paratesticular rhabdomyosarcoma: a case of young adult patient who has inguinal relapse.

Authors:  Murat Kosan; Umut Gonulalan; Ozgur Ugurlu; Selda Seckin; Oztug Adsan
Journal:  Int Urol Nephrol       Date:  2007-02-20       Impact factor: 2.370

2.  Embryonal rhabdomyosarcoma of the testis.

Authors:  Brian Kelly; Dara Lundon; Babatunde Rowaiye; Padraig Daly; Kilian Walsh
Journal:  Can Urol Assoc J       Date:  2011-02       Impact factor: 1.862

3.  Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.

Authors:  David O Walterhouse; Alberto S Pappo; Jane L Meza; John C Breneman; Andrea A Hayes-Jordan; David M Parham; Timothy P Cripe; James R Anderson; William H Meyer; Douglas S Hawkins
Journal:  J Clin Oncol       Date:  2014-09-29       Impact factor: 44.544

4.  Two Cases of Adolescents with Paratesticular Rhabdomyosarcoma Inadequately Treated: The Problem of Referral.

Authors:  Andrea Ferrari; Cristina Meazza; Marco Vajna de Pava; Carlo Alfredo Clerici; Michela Casanova
Journal:  J Adolesc Young Adult Oncol       Date:  2011-09       Impact factor: 2.223

Review 5.  Rhabdomyosarcoma: review of the Children's Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies.

Authors:  Suman Malempati; Douglas S Hawkins
Journal:  Pediatr Blood Cancer       Date:  2012-02-29       Impact factor: 3.167

6.  Paratesticular rhabdomyosarcoma: Importance of initial therapy.

Authors:  William J Hammond; Benjamin A Farber; Anita P Price; Suzanne L Wolden; Todd E Heaton; Leonard H Wexler; Michael P La Quaglia
Journal:  J Pediatr Surg       Date:  2016-11-14       Impact factor: 2.545

7.  Clinicopathological characteristics and treatment outcomes of adult patients with paratesticular rhabdomyosarcoma (PRMS): A 10-year single-centre experience.

Authors:  Serkan Keskin; Meltem Ekenel; Mert Basaran; Isin Kilicaslan; Murat Tunc; Sevil Bavbek
Journal:  Can Urol Assoc J       Date:  2012-02       Impact factor: 1.862

8.  Paratesticular alveolar rhabdomyosarcomas do not harbor typical translocations: a distinct entity with favorable prognosis?

Authors:  Tobias M Dantonello; Christian Vokuhl; Monika Scheer; Monika Sparber-Sauer; Sabine Stegmaier; Guido Seitz; Heike Scheithauer; Jörg Faber; Iris Veit-Friedrich; Peter Kaatsch; Stefan S Bielack; Thomas Klingebiel; Ewa Koscielniak
Journal:  Virchows Arch       Date:  2018-02-21       Impact factor: 4.064

9.  Demographic and Treatment Variables Influencing Outcome for Localized Paratesticular Rhabdomyosarcoma: Results From a Pooled Analysis of North American and European Cooperative Groups.

Authors:  David O Walterhouse; Donald A Barkauskas; David Hall; Andrea Ferrari; Gian Luca De Salvo; Ewa Koscielniak; Michael C G Stevens; Hélène Martelli; Guido Seitz; David A Rodeberg; Margarett Shnorhavorian; Roshni Dasgupta; John C Breneman; James R Anderson; Christophe Bergeron; Gianni Bisogno; William H Meyer; Douglas S Hawkins; Veronique Minard-Colin
Journal:  J Clin Oncol       Date:  2018-10-23       Impact factor: 44.544

10.  Paratesticular sarcomas: our case series.

Authors:  Ülkü Küçük; Ümit Bayol; Emel Ebru Pala; Özlem Akman; Rauf Taner Divrik
Journal:  Turk J Urol       Date:  2013-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.